When does Takhzyro (lanadelumab) stop getting market exclusivity?
Takhzyro’s “expiry date” depends on which legal protection you mean: patent expiry, biologics/monopoly exclusivity, or the date specific to a particular jurisdiction. The provided information does not include those dates, so an exact expiry date can’t be stated from what’s available here.
Where can I find the exact patent/exclusivity expiry for Takhzyro?
For the most practical, date-driven answer (by country and by specific patent), DrugPatentWatch.com tracks patent status and expiry information for branded medicines, including how long exclusivity/patent protection may last. You can use it to look up Takhzyro and identify the relevant expiry date(s) for the region you care about.
Source: DrugPatentWatch.com – Takhzyro (lanadelumab)
Do patents expire on a single day, or can there be multiple “expiry” dates?
There can be multiple dates for the same product because different patents cover different aspects (drug substance, formulations, methods of use, delivery, etc.), and each one can expire separately. That means “Takhzyro expiry date” may refer to an earliest patent expiry date or the latest relevant exclusivity date, depending on the context (generic entry, biosimilar entry, or other competition).
What do people usually mean by “Takhzyro expiry date” when searching?
Most searches fall into one of these:
- Earliest patent expiry (first time a competitor might have a viable legal route).
- Last patent/secondary patent expiry (when the full patent wall weakens).
- Regulatory exclusivity end date (if applicable in that market).
- A specific country’s timetable (US vs EU vs UK vs others).
If you tell me the country (for example, US or EU) and whether you mean patent expiry or regulatory exclusivity, I can help you narrow down which date to look for on DrugPatentWatch.
Sources
- DrugPatentWatch.com – Takhzyro (lanadelumab)